Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment

被引：2

作者：

Tada, Kouki ^{[1
]}

Daizumoto, Kei ^{[1
]}

Takahashi, Masayuki ^{[1
]}

Uehara, Hisanori ^{[2
]}

Tsuda, Megumi ^{[1
]}

Kusuhara, Yoshito ^{[1
]}

Fukawa, Tomoya ^{[1
]}

Yamamoto, Yasuyo ^{[1
]}

Yamaguchi, Kunihisa ^{[1
]}

Kanayama, Hiro-omi ^{[1
]}

机构：

[1] Tokushima Univ, Grad Sch Biomed Sci, Dept Urol, 3-18-15 Kuramoto Cho, Tokushima, Tokushima 7708503, Japan

[2] Tokushima Univ Hosp, Div Pathol, Tokushima, Japan

来源：

IJU CASE REPORTS | 2023年 / 6卷 / 01期

关键词：

molecular-targeted therapy; nivolumab; renal cell carcinoma; sunitinib; MOLECULAR TARGETED THERAPY; CHEMOTHERAPY; INHIBITORS; OUTCOMES; SAFETY;

D O I：

10.1002/iju5.12545

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionA case of multiple liver metastases of clear cell RCC with a significant response to sunitinib as the fifth line after nivolumab is reported.Case presentationThe patient was a 65-year-old man who underwent open nephrectomy for RCC. After the nephrectomy, he had recurrences several times, and metastasectomy had been performed for each recurrence. At 13 years after the nephrectomy, multiple liver, and lung metastases appeared. The treatment was switched to axitinib, followed by cabozantinib, then nivolumab. The best response was PR, SD, and PD for these three drugs, and treatment duration was 14, 3, and 3 months, respectively. As the fifth line, sunitinib was administered, with significant shrinkage of the multiple liver metastases, and PR has been maintained for 34 months.ConclusionSunitinib after an IO-drug showed a significant effect in spite of only slight efficacy with other VEGFR-TKIs, which may have occurred through the alteration of the immunological microenvironment.

引用

页码：41 / 44

页数：4

共 14 条

[1] Treatment outcomes of molecular targeted therapy following nivolumab in metastatic renal cell carcinoma [J].

Bando, Yukari ;

Furukawa, Junya ;

Terakawa, Tomoaki ;

Harada, Kenichi ;

Hinata, Nobuyuki ;

Nakano, Yuzo ;

Fujisawa, Masato .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) :1313-1318

[2] The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma [J].

Barata, Pedro Coelho ;

De Liano, Alfonso Gomez ;

Mendiratta, Prateek ;

Crolley, Valerie ;

Szabados, Bernadett ;

Morrison, Laura ;

Wood, Laura ;

Allman, Kimberly ;

Tyler, Allison ;

Martin, Allison ;

Gilligan, Timothy ;

Grivas, Petros ;

Ornstein, Moshe ;

Garcia, Jorge A. ;

Powles, Thomas ;

Rini, Brian I. .

BRITISH JOURNAL OF CANCER, 2018, 119 (02) :160-163

[3] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[4] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Tannir, N. M. ;

McDermott, D. F. ;

Frontera, O. Aren ;

Melichar, B. ;

Choueiri, T. K. ;

Plimack, Elizabeth R. ;

Barthelemy, P. ;

Porta, C. ;

George, S. ;

Powles, T. ;

Donskov, F. ;

Neiman, V. ;

Kollmannsberger, C. K. ;

Salman, P. ;

Gurney, H. ;

Hawkins, R. ;

Ravaud, A. ;

Grimm, M. -O. ;

Bracarda, S. ;

Barrios, C. H. ;

Tomita, Y. ;

Castellano, D. ;

Rini, B. I. ;

Chen, A. C. ;

Mekan, S. ;

McHenry, M. B. ;

Wind-Rotolo, M. ;

Doan, J. ;

Sharma, P. ;

Hammers, H. J. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) :1277-1290

[5] Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Escudier, B. ;

McDermott, D. F. ;

George, S. ;

Hammers, H. J. ;

Srinivas, S. ;

Tykodi, S. S. ;

Sosman, J. A. ;

Procopio, G. ;

Plimack, E. R. ;

Castellano, D. ;

Choueiri, T. K. ;

Gurney, H. ;

Donskov, F. ;

Bono, P. ;

Wagstaff, J. ;

Gauler, T. C. ;

Ueda, T. ;

Tomita, Y. ;

Schutz, F. A. ;

Kollmannsberger, C. ;

Larkin, J. ;

Ravaud, A. ;

Simon, J. S. ;

Xu, L-A ;

Waxman, I. M. ;

Sharma, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1803-1813

[6] Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Motzer, Robert J. ;

Penkov, Konstantin ;

Haanen, John ;

Rini, Brian ;

Albiges, Laurence ;

Campbell, Matthew T. ;

Venugopal, Balaji ;

Kollmannsberger, Christian ;

Negrier, Sylvie ;

Uemura, Motohide ;

Lee, Jae L. ;

Vasiliev, Aleksandr ;

Miller, Wilson H., Jr. ;

Gurney, Howard ;

Schmidinger, Manuela ;

Larkin, James ;

Atkins, Michael B. ;

Bedke, Jens ;

Alekseev, Boris ;

Wang, Jing ;

Mariani, Mariangela ;

Robbins, Paul B. ;

Chudnovsky, Aleksander ;

Fowst, Camilla ;

Hariharan, Subramanian ;

Huang, Bo ;

di Pietro, Alessandra ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) :1103-1115

[7] Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma [J].

Nadal, R. ;

Amin, A. ;

Geynisman, D. M. ;

Voss, M. H. ;

Weinstock, M. ;

Doyle, J. ;

Zhang, Z. ;

Viudez, A. ;

Plimack, E. R. ;

McDermott, D. F. ;

Motzer, R. ;

Rini, B. ;

Hammers, H. J. .

ANNALS OF ONCOLOGY, 2016, 27 (07) :1304-1311

[8] Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer [J].

Park, Song Ee ;

Lee, Se Hoon ;

Ahn, Jin Seok ;

Ahn, Myung-Ju ;

Park, Keunchil ;

Sun, Jong-Mu .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (01) :106-111

[9] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Rini, Brian I. ;

Plimack, Elizabeth R. ;

Stus, Viktor ;

Gafanov, Rustem ;

Hawkins, Robert ;

Nosov, Dmitry ;

Pouliot, Frederic ;

Alekseev, Boris ;

Soulieres, Denis ;

Melichar, Bohuslav ;

Vynnychenko, Ihor ;

Kryzhanivska, Anna ;

Bondarenko, Igor ;

Azevedo, Sergio J. ;

Borchiellini, Delphine ;

Szczylik, Cezary ;

Markus, Maurice ;

McDermott, Raymond S. ;

Bedke, Jens ;

Tartas, Sophie ;

Chang, Yen-Hwa ;

Tamada, Satoshi ;

Shou, Qiong ;

Perini, Rodolfo F. ;

Chen, Mei ;

Atkins, Michael B. ;

Powles, Thomas .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12) :1116-1127

[10] Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors [J].

Shah, A. Y. ;

Kotecha, R. R. ;

Lemke, E. A. ;

Chandramohan, A. ;

Chaim, J. L. ;

Msaouel, P. ;

Xiao, L. ;

Gao, J. ;

Campbell, M. T. ;

Zurita, A. J. ;

Wang, J. ;

Corn, P. G. ;

Jonasch, E. ;

Motzer, R. J. ;

Sharma, P. ;

Voss, M. H. ;

Tannir, N. M. .

EUROPEAN JOURNAL OF CANCER, 2019, 114 :67-75

← 1 2 →